‘Oppenheimer’ helps IMAX swing to a profit in the third quarter

‘Oppenheimer’ helps IMAX swing to a profit in the third quarter


Christopher Nolan’s ‘Oppenheimer’ movie billboard is seen in Katowice, Poland on July 20, 2023.

Beata Zawrzel | Nurphoto | Getty Images

IMAX on Wednesday posted third quarter earnings showing its second highest-grossing quarter ever at the global box office, led by Universal’s “Oppenheimer.”

Shares slipped about 4% in early trading, however.

Here’s how the company performed in the third quarter compared with Wall Street estimates:

  • Earnings per share: 22 cents vs. 23 cents per share expected, according to LSEG, formerly known as Refinitiv
  • Revenue: $103.9 million vs. $100.7 million expected, according to LSEG, formerly known as Refinitiv

The movie company reported a net income of $12 million, or 22 cents a share, versus a loss of $9 million, or 16 cents a share, a year earlier. Revenue was $103.9 million, up 51% year-over-year.

Key contributors to the third quarter’s growth included Hollywood titles like “Oppenheimer,” which raked in more than $180 million in revenue, along with “Mission: Impossible: Dead Reckoning Part 1” and “Indiana Jones and the Dial of Destiny.” Local language films also contributed to the company’s summer success, including Chinese title “Creation of the Gods: Kingdom of Storms” and India’s “Jawan.”

The quarter was behind only the fourth quarter of 2019 in terms of grosses, IMAX said.

In the third quarter, IMAX also generated 120 new signings for new and upgraded IMAX systems across the world.

“It is truly the best of times at IMAX. The company delivered a record performance in the third quarter,” CEO Richard Gelfond said during the company’s earnings call. “We’ve seen many good quarters, but few have exceeded our expectations like this.”

Chief Financial Officer Natasha Fernandes added that the company’s operating cash flow is more than three times what it was last year.

Looking to next year, IMAX expects “some movement” due to impacts felt from the Hollywood actors’ strike, Gelfond said. But the company is optimistic that upcoming titles like IMAX-shot “Dune: Part 2” – now slated for a March 2024 release – combined with this quarter’s growth will anchor the first quarter box office.

Even as entertainment pushes forward into a post-pandemic arena, with streaming dominant, Gelfond said the company’s strength shows that the theatrical experience is not dead.

“We’ve really delivered this quarter across every imaginable index, whether it’s financial, or whether it’s signing, or whether its our position in the ecosystem, or even in small ways many of you don’t see which is in our leverage in the day-to-day business,” Gelfond said on the call. “I’ve certainly rarely been as confident as I am today.”

Disclosure: NBCUniversal, the parent company of CNBC, also owns Universal Pictures, which released “Oppenheimer.”



Source

Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More